Cargando…
Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice
SIMPLE SUMMARY: Triple-negative breast cancer has been historically considered an orphan disease in terms of therapeutic options. To date, chemotherapy is still the mainstay of treatment both in the early and metastatic settings. Recent advances in the genomic and immunologic fields have revealed th...
Autores principales: | Carlino, Francesca, Diana, Anna, Piccolo, Antonio, Ventriglia, Anna, Bruno, Vincenzo, De Santo, Irene, Letizia, Ortensio, De Vita, Ferdinando, Daniele, Bruno, Ciardiello, Fortunato, Orditura, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103968/ https://www.ncbi.nlm.nih.gov/pubmed/35565233 http://dx.doi.org/10.3390/cancers14092102 |
Ejemplares similares
-
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
por: Diana, Anna, et al.
Publicado: (2020) -
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
por: Diana, Anna, et al.
Publicado: (2022) -
HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study
por: Carlino, Francesca, et al.
Publicado: (2022) -
Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis
por: Pompella, Luca, et al.
Publicado: (2020) -
PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)